Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

Congratulation to the teams at Daybreak Partners portfolio company Arcturus Therapeutics and DukeNUS on their receipt of approval from the Singapore HSA to proceed with Phase 1 /2 Clinical Trial for a COVID vaccine!